Savara

Update in progress

SVRA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases in the United States. Its lead candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor being developed in Phase 3 for autoimmune pulmonary alveolar proteinosis. Founded in 2007, Savara is headquartered in Langhorne, Pennsylvania.

Company score

Sentiment: 0.02; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.30; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.06; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive